Literature DB >> 11207272

Anergy and not clonal ignorance determines the fate of B cells that recognize a physiological autoantigen.

M Rojas1, C Hulbert, J W Thomas.   

Abstract

Autoantibodies to insulin arise spontaneously in the insulin autoimmune syndrome and in type I diabetes. In addition, administration of insulin to individuals without autoimmune disease routinely results in Abs that bind autologous hormone. These observations and findings in transgenic models of tolerance led to an inference that physiological levels of hormones and growth factors, such as insulin, are not sufficient to induce tolerance in B cells, a state termed clonal ignorance. In contrast, we have discovered that virtually all conventional B cells expressing a low affinity anti-insulin transgene interact with endogenous insulin and are effectively silenced for Ig production and for T cell-dependent immune responses. A fraction of transgenic B cells escapes silencing and functions autonomously to produce insulin Abs that may lower fasting blood sugars similar to an insulin autoimmune syndrome. These B cells have characteristics of a B1-like subset and are depleted by hypotonic peritoneal lysis. These findings question the concept of clonal ignorance and show that physiological concentrations of Ag may effectively silence conventional B cells even when the affinity for autoantigen is low. Self-reactivity may arise in the repertoire because of compartmental differences that govern the fate of B cells and not as a result of true clonal ignorance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207272     DOI: 10.4049/jimmunol.166.5.3194

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  Antigen-specific responses in autoimmunity and tolerance.

Authors:  J W Thomas
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Longitudinal epitope analysis of insulin-binding antibodies in type 1 diabetes.

Authors:  T R Hall; J W Thomas; C J Padoa; C Torn; M Landin-Olsson; E Ortqvist; C S Hampe
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

3.  Anti-Insulin B Cells Are Poised for Antigen Presentation in Type 1 Diabetes.

Authors:  Jamie L Felton; Damian Maseda; Rachel H Bonami; Chrys Hulbert; James W Thomas
Journal:  J Immunol       Date:  2018-06-27       Impact factor: 5.422

4.  The Autoimmune Risk Variant PTPN22 C1858T Alters B Cell Tolerance at Discrete Checkpoints and Differentially Shapes the Naive Repertoire.

Authors:  Genita Metzler; Xuezhi Dai; Christopher D Thouvenel; Socheath Khim; Tania Habib; Jane H Buckner; David J Rawlings
Journal:  J Immunol       Date:  2017-08-11       Impact factor: 5.422

5.  Bruton's Tyrosine Kinase Synergizes with Notch2 To Govern Marginal Zone B Cells in Nonobese Diabetic Mice.

Authors:  James B Case; Rachel H Bonami; Lindsay E Nyhoff; Hannah E Steinberg; Allison M Sullivan; Peggy L Kendall
Journal:  J Immunol       Date:  2015-06-01       Impact factor: 5.422

6.  Innate stimulation of B1a cells enhances the autoreactive IgM repertoire in the NOD mouse: implications for type 1 diabetes.

Authors:  J Côrte-Real; N Duarte; L Tavares; C Penha-Gonçalves
Journal:  Diabetologia       Date:  2012-03-01       Impact factor: 10.122

7.  NFATc2 (NFAT1) assists BCR-mediated anergy in anti-insulin B cells.

Authors:  Rachel H Bonami; William T Wolfle; James W Thomas; Peggy L Kendall
Journal:  Mol Immunol       Date:  2014-02-06       Impact factor: 4.407

8.  Bruton's tyrosine kinase promotes persistence of mature anti-insulin B cells.

Authors:  Rachel H Bonami; Allison M Sullivan; James B Case; Hannah E Steinberg; Kristen L Hoek; Wasif N Khan; Peggy L Kendall
Journal:  J Immunol       Date:  2014-01-22       Impact factor: 5.422

9.  B cells in autoimmune diabetes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2005-11-10

10.  B lymphocyte "original sin" in the bone marrow enhances islet autoreactivity in type 1 diabetes-prone nonobese diabetic mice.

Authors:  Rachel A Henry-Bonami; Jonathan M Williams; Amita B Rachakonda; Mariam Karamali; Peggy L Kendall; James W Thomas
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.